24 results
8-K
EX-10.1
INMB
INmune Bio Inc
26 Apr 24
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:28pm
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
8-K
EX-10.1
INMB
INmune Bio Inc
22 Apr 24
Entry into a Material Definitive Agreement
5:10pm
, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union
8-K
EX-99.1
INMB
INmune Bio Inc
15 Nov 23
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
4:13pm
approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries
8-K
EX-10.1
INMB
INmune Bio Inc
24 Mar 22
Entry into a Material Definitive Agreement
4:00pm
of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary
8-K
EX-10.1
5ivchrj
15 Jul 21
Inmune Bio, Inc. Announces $40 Million
4:41pm
8-K
EX-1.1
3cz3w
11 Mar 21
Entry into a Material Definitive Agreement
12:00am
8-K/A
EX-4.1
bpfd40thwinnlj2m
4 Jan 21
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
wrbajm8
30 Dec 20
Entry into a Material Definitive Agreement
4:57pm
8-K
EX-1.1
qyahke 402xu0rg
16 Jul 20
INmune Bio, Inc. Prices Public Offering of Common Stock
9:27am
8-K
EX-1.1
3iei2wl9dxvv
17 Apr 20
Entry into a Material Definitive Agreement
12:00am
424B3
rj2iw946
26 Jul 19
Prospectus supplement
4:40pm
424B3
er5l6j8
3 Jul 19
Prospectus supplement
1:03pm
10-K
lc3ytm wg
29 Mar 19
Annual report
5:28pm